The clinical trials industry is moving fast on AI. The assumption underneath most of that momentum, that better tooling will narrow the performance gap between site teams, deserves a direct challenge. AI does not close the readiness divide. Applied to the work of running a trial, it is more likely to widen it.
By leveraging the Fresh Start Effect at site initiation and shifting from passive training to demonstrated readiness, sponsors and CROs can turn trial launch into a powerful multiplier for early performance, compliance, and execution quality.